title: Plasma hydroxy-metronidazole/metronidazole ratio in hepatitis C virus-induced liver disease.
abstract: It has been suggested that the measurement of metronidazole clearance is a sensitive method for evaluating liver function. The aim of this study was to evaluate the usefulness of plasma hydroxy-metronidazole/metronidazole ratios as indicators of dynamic liver function to detect changes resulting from the various forms of chronic hepatitis C virus (HCV) infection. A total of 139 individuals were studied: 14 healthy volunteers, 22 healthy, asymptomatic, consecutive anti-HCV-positive HCV-RNA negative subjects, 81 patients with chronic hepatitis C (49 with moderate/severe chronic hepatitis and 34 with mild hepatitis), and 20 patients with cirrhosis of the liver. HCV status was determined by the polymerase chain reaction. Plasma concentrations of metronidazole and its hydroxy-metabolite were measured by reverse-phase high-performance liquid chromatography with ultraviolet detection in a blood sample collected 10 min after the end of a metronidazole infusion. Anti-HCV-positive HCV-RNA-negative individuals demonstrated a significantly reduced capacity to metabolize intravenously infused metronidazole compared to healthy individuals (0.0478 +/- 0.0044 vs 0.0742 +/- 0.0232). Liver cirrhosis patients also had a reduced plasma hydroxy-metronidazole/metronidazole ratio when compared to the other groups of anti-HCV-positive individuals (0.0300 +/- 0.0032 vs 0.0438 +/- 0.0027 (moderate/severe chronic hepatitis) vs 0.0455 +/- 0.0026 (mild chronic hepatitis) and vs 0.0478 +/- 0.0044 (anti-HCV-positive, HCV-RNA-negative individuals)). These results suggest an impairment of the metronidazole metabolizing system induced by HCV infection that lasts after viral clearance. In those patients with chronic hepatitis C, this impairment is paralleled by progression of the disease to liver cirrhosis.
authors.affiliation: Unidade Integrada de Farmacologia e Gastroenterologia, Faculdade de Medicina, Universidade São Francisco, Bragança Paulista, SP, Brasil.
authors.forename: M A M
authors.initials: MA
authors.lastname: Marchioretto
authors.forename: C
authors.initials: C
authors.lastname: Ecclissato
authors.forename: C M F
authors.initials: CM
authors.lastname: da Silva
authors.forename: N M
authors.initials: NM
authors.lastname: Cassiano
authors.forename: S A
authors.initials: SA
authors.lastname: Calafatti
authors.forename: S
authors.initials: S
authors.lastname: Mendonça
authors.forename: M L
authors.initials: ML
authors.lastname: Ribeiro
authors.forename: G C R
authors.initials: GC
authors.lastname: Bernasconi
authors.forename: M F
authors.initials: MF
authors.lastname: Degger
authors.forename: H
authors.initials: H
authors.lastname: Piovesan
authors.forename: J
authors.initials: J
authors.lastname: Pedrazzoli
mesh_terms: D000328:Adult; D000890:Anti-Infective Agents / Q000097:blood; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D002851:Chromatography, High Pressure Liquid; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis* / Q000209:etiology; D008111:Liver Function Tests; D008297:Male; D008795:Metronidazole / Q000031:analogs & derivatives / Q000097:blood; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012720:Severity of Illness Index; D019562:Viral Load
chemical_list: D000890:Anti-Infective Agents; D015415:Biomarkers; D008795:Metronidazole